Evidence map›Paper›PMID 42145593›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Priming of Multiple HIV Neutralizing B Cell Precursors in Humans.

Chen-Hao Yeh, Stephen R Walsh, Ruth J Parsons, Qianyi E Zhang, Bhishem Thakur, Kijun Song, Kejun Liu, Hélène Fradin Kirshner, Elizabeth Van Ltallie, Matthew Clark and 52 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

62 authors.

Chen-Hao YehDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Stephen R WalshMass General Brigham, Boston, MA 02119, USA.
Ruth J ParsonsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Qianyi E ZhangDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Bhishem ThakurDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Kijun SongDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Kejun LiuDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Hélène Fradin KirshnerDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Elizabeth Van LtallieDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Matthew ClarkDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
William O HahnFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Shengli SongDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
Liwen LinDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Hsin-I HuangDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Jade LugoDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Alex QuanDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Yue XueDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Yue ChenDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Ryan TuckDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Katayoun MansouriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Taylor N SpenceDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Helena A LaukaitisDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Rob ParksDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Margaret BarrDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Elise SchweerDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Nicholas LeveringDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Amanda EatonDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
Shaunna ShenDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
Katarzyna JanowskaDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Victor IlevbareDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Graham JohnsonDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Peng WangDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Derek CainDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Aria Arus-AltuzDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Elizabeth DonahueDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Ilya ZhbannikovDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Madison BerryDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Sravani VenkatayogiDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Joshua S Martin BeemDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Ollivier HyrienFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Pei-Chun YuFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Laura L PolakowskiNational Institute of Allergy and Infectious Diseases.
India TindaleFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Claudio YurdadonFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Randy BurnhamFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Jessica AndriesenFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Kshitij WaghDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Michael S SeamanHarvard Medical School, Boston, MA 02115, USA.
Emmanuel B WalterDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Garnett KelsoeDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
M Juliana McElrathFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Lawrence CoreyFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Kenneth MayerHarvard Medical School, Boston, MA 02115, USA.
Persephone BorrowCentre for Immuno-Oncology, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
Wilton WilliamsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Kevin WieheDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
David MontefioriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Robert J EdwardsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Priyamvada AcharyaDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Lindsey BadenMass General Brigham, Boston, MA 02119, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI KELSOE, GARNETT H · 2012 to 2018
$204.7M
Nonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodiesUM1AI144371 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2025
$190.4M
HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
Harvard Medical School Vaccine Clinical Trials UnitUM1AI069412 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Lindsey Robert Baden, Daniel R. Kuritzkes · 2012 to 2026
$57.2M
Project 3 - Dynamics of latent HIV-1 reservoirs: High resolution antigenic mapping and strategies to block reboundU54AI170752 · NIAID · DUKE UNIVERSITY · PI Priyamvada Acharya · 2022 to 2026
$32.0M
Targeting early metastable intermediates of the SARS-CoV-2 spike for vaccine and therapeutics developmentR01AI145687 · NIAID · DUKE UNIVERSITY · PI Priyamvada Acharya · 2019 to 2026
$6.9M
Data commons for 'omic, microscopy and analysis core facilitiesS10OD018164 · OD · DUKE UNIVERSITY · PI WRAY, GREGORY A. · 2014 to 2014
$598k
PacBio Sequel IIe for GCB Sequencing CoreS10OD034222 · OD · DUKE UNIVERSITY · PI SWAIN, DEVJANEE · 2023 to 2023
$498k
NCRR NIH HHS UL1 RR025758NIAID NIH HHS R01 AI145687NIAID NIH HHS U54 AI170752NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI069412NIAID NIH HHS UM1 AI100645NIAID NIH HHS UM1 AI144371NIH HHS S10 OD018164NIH HHS S10 OD034222
6 · The paper itself

Abstract

Induction of broadly neutralizing antibodies (bnAbs) remains a major goal of HIV vaccine development. In a Phase I clinical trial, we evaluated the immunogenicity of CH505 transmitted/founder (TF) envelope trimer designed to prime precursors of the heavy chain third complementarity determining region (CDRH3)-dominant class of CD4-binding site (CD4bs) HIV bnAbs. Neutralizing memory B-cell lineages were isolated from all vaccine recipients, including lineages targeting the CD4bs, V1/V3, and gp120/gp41 interface. Candidate CDRH3-dominant, CD4bs bnAb precursor lineages were identified in 73% of vaccinees, including one lineage that exhibited limited heterologous neutralization of global HIV-1 isolates. Structural analyses defined the modes of Env recognition by these three antibody classes. Together, these findings demonstrate that immunization with the CH505 TF trimer can prime a diverse, polyclonal repertoire of bnAb precursor lineages in humans, providing multiple starting points for sequential immunization strategies aimed at eliciting broadly neutralizing HIV-1 antibodies.

Indexed as

B cellclinical trialHuman Immunodeficiency Virusneutralizing antibodytransmitted/founder virusvaccine

Identifiers

PMID42145593
PMCPMC13174844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.